YnetnewsHealth
Weekly Insulin Injections Approved in US, Set for Israeli Market
Summarized from Ynetnews by baba
CenterNeutral tone
Plus
The FDA has approved Eli Lilly's Onswik, a weekly long-acting insulin for type 2 diabetes, with a rival drug, Awiqli, expected in Israel by November. Both treatments aim to reduce daily injections for patients managing blood sugar levels.
The story in 6 lines · by baba
- Weekly insulin Onswik approved by FDA for type 2 diabetes.
- Onswik aims to reduce patient injections by over 300 annually.
- Rival weekly insulin Awiqli to launch in Israel in November.
- Weekly injections replace basal insulin, not mealtime insulin.
- Trials show Onswik is as effective as daily insulin.
- Hypoglycemia is the most common side effect.
Ynetnews publishes in English. The key points are summarized above. Read Ynetnews’s full report from the link at the top of the page.
Mentioned
Full coverage · 3 outlets
First: Ynet · Sep 26The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 1Other 1
Related stories · 2
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
